Why TIGLUTIK (riluzole) now?
For more than 20 years, physicians have relied on riluzole as a foundational therapy for their patients diagnosed and living with amyotrophic lateral sclerosis (ALS). Now TIGLUTIK is available, the first and only oral suspension alternative to riluzole tablets specifically designed for people living with ALS who have or may develop dysphagia.1-3
Unpredictable onset of dysphagia
More than 80% of patients develop dysphagia at some point, and despite being present in about one-third of patients at disease onset, it often goes unrecognized.3
Why wait for dysphagia—when it can strike at any time?
There are hazards around dysphagia and swallowing crushed tablets4:
- Patients tend to adapt to slowly deteriorating swallowing function by changing or modifying their foods, drinks, and medicine4
- Dosage errors may result from incomplete delivery of medicine3
- Using alternative methods to administer oral medications may change how the drug is absorbed by the body, potentially affecting its safety and efficacy3
Prescribe TIGLUTIK at diagnosis
- U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Rilutek (riluzole) NDA 20599 S-013 approval package. November 16, 2009.
- TIGLUTIK (riluzole) [package insert]. Berwyn, PA: ITF Pharma; September 2018.
- Keating GM. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect. 2016;32(7):282-286.
- Onesti E, Schettino I, Gori MC, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94. doi:10.3389/fneur2017.00094.
- Rilutek (riluzole) [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; April 2016.
- Data on file. ITF Pharma. Berwyn, PA. September 2018.
- Barnett N, Parmar P. How to tailor medication formulations for patients with dysphagia. Pharm J. 2016;297(7892). doi: 10.1211/PJ.2016.20201498.